Senesco Technologies

Senesco initiates dosing in SNS01-T study

Thursday, November 3, 2011

Senesco Technologies has initiated dosing in its phase Ib/IIa clinical study of SNS01-T at the Mayo Clinic in Rochester, MN. The study is an open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients.

[Read More]